Development of antiobesity medication has not been easy, because of unexpected adverse events
The Results Participants receiving 7.2 mg semaglutide achieved a mean weight loss of 20.7% at 72 weeks, compared to 17.5% in the 2.4 mg group, and 2.4% in the placebo group. Over 30% of participants on the 7.2 mg dose lost 25% or more of their body weight
In humans, C-cells contain far fewer GLP-1 receptors, which suggests a much lower risk for similar outcomes
Semaglutide (Wegovy) for Weight Loss: In large clinical trials (the STEP trials), patients taking Wegovy combined with diet and exercise lost an average of 15% of their initial body weight over 68 weeks
10.1016/j.biopha.2015.10.026 52 GanaiA
Before age 65, an HSA withdrawal for a non-qualified expense triggers ordinary income tax plus a 20% excise tax on the amount